Owkin

Owkin documents MSIntuit CRC validation across five external cohorts comprising more than 1,500 biopsies and 500 surgical resections. The external-cohort evaluation adds scientific validation evidence independent of previously recorded commercial agreements.

Owkin has multi-year K Pro agreements with Sanofi and AstraZeneca, licenses K Pro to Servier and Boehringer Ingelheim, and is testing K Pro in real clinical/research workflows at Gustave Roussy.

Owkin has multi-year K Pro agreements with Sanofi and AstraZeneca, licenses K Pro to Servier and Boehringer Ingelheim, and is testing K Pro in real clinical/research workflows at Gustave Roussy.

Owkin is building K Pro, an agentic AI Scientist for biomedical research that autonomously orchestrates AI skills and tools on a multimodal patient-data network; its scientific stack also includes first-in-class AI diagnostics and peer-reviewed biomedical AI research.

Owkin develops K Pro, an AI scientist combining multimodal patient data with specialized biological agentic AI across drug discovery and development.

Owkin develops K Pro, an AI scientist combining multimodal patient data with specialized biological agentic AI across drug discovery and development.

Owkin reports $304.1M in cumulative investment from institutional and strategic investors including Bpifrance, GV, Mubadala, Sanofi and Bristol Myers Squibb; its long-term Sanofi relationship expanded in 2026 into a multi-year K Pro agent collaboration backed by a five-year license.

Owkin combines AI research, multimodal patient data networks, pharma partnerships and its own clinical-stage oncology program, including the INVOKE Phase 1a/1b trial.

Owkin combines AI research, multimodal patient data networks, pharma partnerships and its own clinical-stage oncology program, including the INVOKE Phase 1a/1b trial.

Owkin released Substra for collaborative model training without centralizing source data, hosted under Linux Foundation governance, and released FLamby for federated-learning experiments across data modalities.

Foundation-model, agent and multimodal-data skills transfer broadly, while oncology, biology and drug-development specialization limit full cross-market portability.

Foundation-model, agent and multimodal-data skills transfer broadly, while oncology, biology and drug-development specialization limit full cross-market portability.